Foundation Medicine
In Brief This Week: Myriad Genetics, Thermo Fisher Scientific, DeepUll, Roche, Immunovia, More
News items for the weeks of Nov. 25 and Dec. 2, 2024.
Pathologists See Value Balance Shift Toward Comprehensive Sequencing for Hematologic Cancers
Premium
At the AMP annual meeting last week, speakers at multiple workshops said their field is reaching a tipping point as the clinical utility of NGS further solidifies.
Foundation Medicine Companion Dx Test Gets FDA OK for Use with Merck's Tepmetko in Lung Cancer
The blood-based comprehensive genomic profiling test uses next-generation sequencing to analyze 324 genes.
Foundation Medicine Test Approved by FDA as CDx for Itovebi in Breast Cancer Patients
The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
Foundation Medicine Nabs Five-Year VA Contract for Tumor Molecular Profiling of Cancer Patients
The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.
Jul 24, 2024
Nov 2, 2023